@article{474770ea83bd47c89d5ccbaa5f17f421,
title = "Re: Neoadjuvant PD-L1 plus CTLA-4 Blockade in Patients with Cisplatin-ineligible Operable High-risk Urothelial Carcinoma",
author = "Einerhand, {Sarah M. H.} and {van Dorp}, Jeroen and {van der Heijden}, {Michiel S.} and {van Rhijn}, {Bas W. G.}",
note = "Funding Information: Conflicts of interest: Michiel S. van der Heijden has received institutional research funding from Bristol-Meyers Squibb, 4SC, and Roche, and institutional consultancy fees from Bristol-Meyers Squibb, Roche, Merck Sharp & Dohme, AstraZeneca, Pfizer, Janssen, and Seattle Genetics. Bas W.G. van Rhijn has received consultancy fees from Ferring and QED Therapeutics. The remaining authors have nothing to disclose.",
year = "2023",
month = jan,
doi = "https://doi.org/10.1016/j.eururo.2022.09.024",
language = "English",
volume = "83",
pages = "91--92",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "1",
}